ClinicalTrials.Veeva

Menu

Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress (HBOT)

S

Steward St. Elizabeth's Medical Center of Boston, Inc.

Status

Completed

Conditions

Covid19

Treatments

Other: Hyperbaric Oxygen Therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT04800120
IRB Protocol #00800

Details and patient eligibility

About

Investigate whether hyperbaric oxygen therapy treatment can become a viable treatment option for COVID-19. If successful, providers will be able to provide future COVID-19 patients with mild-to-moderate respiratory distress hyperbaric oxygen therapy in order to help avoid mechanical ventilation

Full description

Using the Monoplace Hyperbaric Oxygen Chambers we will be providing COVID- 19 positive patients with mild-to-moderate distress 100% oxygen at 2.0 ATA for 90 minutes on consecutive days for a total of up to 5 treatments. A comparison will be made using a historical cohort not receiving HBOT. Data will be collected to determine whether or not HBOT is of any benefit to COVID-19 positive patient with mild-to-moderate respiratory distress.

Study Group: Provide 100% oxygen at 2.0 ATA for 90 minutes on consecutive days for a total of up to 5 treatment to COVID-19 patients meeting inclusion criteria Control Group: Any COVID-19 positive patient meeting study inclusion criteria that does not receive HBOT (historical) The control group is further defined as patients who were previously treated for COVID-19 at Morton Hospital that did not receive hyperbaric oxygen therapy. This will require accessing medical records to obtain patient information to establish the historical control data metric.

Study outcome measures:

  • Time to normalize 02 requirement (ambient air pulse ox greater than or equal to 92% or ABG w/Pa02 greater than 60mmHG on air)
  • Mortality
  • Days free of invasive mechanical ventilation

Enrollment

6 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Verified COVID-19 infection
  • Patient w/02 dependence of less than or equal to 6 liter/min to maintain pulse ox greater than or equal to 92% or arterial gas w/PA02 greater than 60mm HG

Exclusion criteria

  • Not diagnosed w/COVID-19 infection
  • Pregnancy
  • DNR or other restrictions in escalation of level of care
  • Contraindication for HBO
  • Blood pressure parameters which are deemed unstable by clinical team
  • Patients who require continuous ECG and/or continuous blood pressure monitoring, and with arterial lines
  • Patients requiring rewarming
  • Patients requiring any kind of invasive catheter/pressure monitoring
  • Patients requiring continuous support of intravenous medication
  • Minor subject (less than 18 years old)
  • Refusal to participate
  • Signs of respiratory decompensation requiring intubation and mechanical ventilation
  • 02 dependence greater than or equal to 6L/minute to obtain Sa02 greater than or equal to 92% or ABG w/Pa02 >60mmHg

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

6 participants in 2 patient groups

Study Group
Active Comparator group
Description:
Identified COVID 19 patients receiving the intervention of Hyperbaric Oxygen Therapy
Treatment:
Other: Hyperbaric Oxygen Therapy
Control Group
No Intervention group
Description:
Historical control of COVID 19 patients who were previously treated and did not receiving Hyperbaric Oxygen Therapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems